Effective immediately, PathGroup will discontinue Cystine, Urine Random (Test Code: CYSTE) and replace it with Cystine (Quantitative), 24 Hour Urine (Test CodeL CYSQTU).
Click here to learn more.
Search Results for
PathGroup Selected by NIH to Become RADx Program “Mega-Lab” for COVID-19 Testing
NASHVILLE, Tenn. – (September 2, 2020) – PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced the award of a funding grant from the National Institutes of Health (NIH) under the Rapid Acceleration of Diagnostics (RADx SM) program. PathGroup will utilize the funds granted by the NIH to expand its high-throughput COVID-19 testing laboratory, becoming one of the nation’s “mega-labs” with the capability of performing up to 80,000 SARS-CoV-2 tests per day for COVID-19, with results expected to be delivered within 24 hours.
The RADxSM initiative supports the development, production scale-up, and deployment of accurate, rapid SARS-CoV-2 tests across the country. The RADx-Advanced Technology Platforms (RADx-ATP) program assists in the expansion of labs that can significantly scale the number of COVID-19 tests that can be performed each day in the United States.
Click here to read more.
PathGroup Selected as Early Access Partner for Launch of Illumina’s Sequencing-Based COVID-19 Diagnostic Test
NASHVILLE, Tenn. – (June 23, 2020) – PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced that the company has been selected as an early access partner for the launch of Illumina’s new sequencing-based COVID-19 test, COVIDSeq™. COVIDSeq accommodates more than 3,000 test samples per run, allowing for a substantial increase in testing capacity.
Illumina, a global leader in sequencing technologies, received the first Emergency Use Authorization from the U.S. Food and Drug Administration for a sequencing-based test on June 9, 2020. COVIDSeq is being rolled out via a limited number of early access sites around the world including PathGroup’s comprehensive 140,000 square foot Nashville-area laboratory.
Click Here to read more.
Test Update: Report Interpretation Change-Urine Cultures
Effective June 12, 2020, PathGroup will include additional report interpretation information for results <10,000CFU/ml for urine cultures (Test Code: CXURN) and for cultures performed after a reflex from urinalysis (Test Code: UA2CX).
Click here for more information.
Test Update: Component and CPT Code Additions Autoimmune Liver Disease Reflexive Panel (AILD)
Effective immediately, new components will be added to the Autoimmune Liver Disease Reflexive Panel (Test Code: AILD) which will result in additional billed CPT codes.
Click here for more information.
PathGroup Announces New COVID-19 Testing Option
NASHVILLE, Tenn. – (June 1, 2020) – PathGroup, one of the largest private providers of pathology, clinical and molecular laboratory services in the United States, today announced the availability of a new, minimally-invasive nasal swab collection option as a part of its comprehensive SARS-CoV-2 (COVID-19) testing program.
Many current molecular diagnostic COVID-19 tests rely on a nasopharyngeal (NP) swab, which can cause discomfort for patients during the collection process. The new nasal swab collection option is more comfortable for patients and easier for healthcare providers to administer.
Click here for more information.
Test Available: SARS-CoV-2 (COVID-19) Antibody
Effective May 27, 2020, PathGroup is pleased to announce the availability of a new serologic test for human antibodies to SARS-Cov-2, the viral pathogen associated with COVID-19 (PathGroup Test Code: COVIDAB). On May 3, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Roche Elecsys® SARS-CoV-2 antibody test. The test is for the qualitative detection of total antibodies (including IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection. This test may aid in identification of patients with an adaptive immune response to SARS‑CoV‑2, indicating recent or prior infection to the SARS-CoV-2 virus.
Click Here to for more information.
Test Update: Coronavirus Disease 2019 Nasal Specimen Collection
Effective May 18, 2020, PathGroup will accept nasal (anterior nares) specimen collection for the SARS-CoV-2, RNA test (PathGroup Test Code: COVID19) when collected with the Hologic® Aptima® Multitest Swab Specimen Collection Kit.
Click Here for more information.
Test Update: Ova/Parasite Exam Specimen Requirement Change
Effective June 8, 2020, the following Ova/Parasite tests will change specimen collection containers. For all Ova/Parasite orders placed on or after June 8, Total-Fix collection vials are required for the collection of stool needed for testing. All previous specimen containers will be discontinued. There will be no change in billed CPT codes.
Click here for more information.
Test Update: TICKID Specimen Requirement Change
Effective immediately, the Tick Identification test (Test Code: TICKID) should be collected and transported in saline or ethanol in a clean container.
Click here for more information.